Ratings XOMA Corporation Nasdaq

Equities

XOMAO

US98419J4040

Market Closed - Nasdaq Other stock markets 04:30:01 2024-07-09 pm EDT			5-day change	1st Jan Change
25.04 ^USD	+0.16%		-1.42%	-0.32%

Jul. 09	Xoma Changes Name to Xoma Royalty	MT
Jul. 01	XOMA Corporation(NasdaqGM:XOMA) added to Russell 3000 Growth Index	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For several months, analysts have been revising their EPS estimates roughly upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the past year, analysts have significantly revised downwards their profit estimates.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
XOMA CORPORATION	-0.32%	286M	-
VERTEX PHARMACEUTICALS INCORPORATED	+19.44%	125B	B+
REGENERON PHARMACEUTICALS, INC.	+20.01%	114B	B+
ARGENX SE	+22.53%	26.73B	B
BIONTECH SE	-23.72%	19.43B	B+
GENMAB A/S	-17.63%	16.22B	A-
BEIGENE, LTD.	-19.87%	15.33B	B
SAREPTA THERAPEUTICS, INC.	+55.81%	14.2B	C+
NEUROCRINE BIOSCIENCES, INC.	+8.76%	14.42B	C+
WUXI APPTEC CO., LTD.	-48.79%	14.33B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes